HGH Fragment 176-191: Research Evidence, Lipid Metabolism and AOD-9604 Differences

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone (hGH). Research on this region of the hormone dates back several decades and has examined metabolic effects including glucose regulation, lipogenesis, lipolysis and fat oxidation in experimental models.

The subject can be confusing because HGH Fragment 176-191, hGH 177-191 and AOD-9604 are closely related but not identical molecules. This guide explains the differences, reviews what the published research actually shows, and separates preclinical findings from later human development work.

What Is HGH Fragment 176-191?

Human growth hormone is a 191-amino-acid protein. HGH Fragment 176-191 refers to a short peptide derived from the hormone’s C-terminal end, covering amino acids 176 through 191.

Researchers began studying short C-terminal fragments of hGH because different regions of the full hormone appeared capable of producing distinct metabolic effects. Early work compared several fragments, including sequences 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191.

HGH Fragment Research at a Glance

Research area What has been studied
Molecular origin C-terminal sequence of human growth hormone
Early metabolic research Blood glucose, insulin sensitivity and adipose-tissue metabolism in animal models
Lipid-metabolism research Antilipogenic activity, lipolysis and fat oxidation in related C-terminal fragments
AOD-9604 relationship A modified analogue based on hGH 177-191 rather than an identical copy of HGH Fragment 176-191
Human efficacy evidence Limited for HGH Fragment 176-191 itself; later human development mainly involved AOD-9604
Key limitation Related fragments should not be treated as interchangeable when interpreting studies

Why the C-Terminal Region of Growth Hormone Was Studied

Growth hormone influences many biological systems, including growth, glucose regulation and lipid metabolism. Researchers investigated shorter portions of the hormone to determine whether some metabolic actions could be separated from the full protein’s broader endocrine effects.

A 1978 study tested several synthetic C-terminal fragments in rats, including hGH 176-191. Some of the fragments produced short-lived changes in blood glucose and insulin sensitivity under the experimental conditions used. This early work showed that the biological activity of the C-terminal region depended not only on sequence length but also on molecular configuration.

HGH 176-191 vs HGH 177-191

The names are sometimes used loosely online, but one amino acid matters when discussing published research. HGH Fragment 176-191 includes amino acid 176, whereas hGH 177-191 begins one residue later.

Much of the frequently cited lipid-metabolism literature was performed specifically on hGH 177-191. A 1993 study reported antilipogenic activity from the 177-191 sequence in rat adipose-tissue experiments. Importantly, that study did not find a significant lipolytic effect using its glycerol-release measure.

This is a useful distinction because “reduced fat synthesis” and “increased fat breakdown” are not the same biological endpoint. Marketing summaries often combine them, whereas the underlying experiments measured them separately.

What Does the Lipid-Metabolism Research Show?

Older C-terminal-fragment studies suggested that this region of hGH can influence adipose-tissue metabolism, but the results vary depending on the exact fragment and experimental model.

Research on hGH 177-191 reported suppression of lipogenesis in animal adipose tissue. Other related analogues were later studied in obese rodent models for effects on fat oxidation, lipolysis and body-weight gain. These findings helped motivate development of modified analogues such as AOD-9604.

Researchers should therefore avoid reducing the evidence to a single claim such as “the fragment burns fat.” The literature includes several different endpoints:

  • lipogenesis, meaning synthesis and storage of lipid;
  • lipolysis, meaning breakdown of stored triglyceride;
  • fat oxidation, meaning metabolic use of fatty acids;
  • body-weight gain in animal models;
  • glucose and insulin responses.

How Is AOD-9604 Different?

AOD-9604 is related to the same C-terminal region but is not identical to HGH Fragment 176-191. Published analytical literature describes AOD-9604 as the hGH 177-191 sequence with an additional tyrosine residue at the N-terminus.

That structural modification matters when comparing studies. Findings generated with AOD-9604 should not automatically be attributed to unmodified HGH Fragment 176-191, and vice versa.

What Did AOD-9604 Animal Studies Find?

In obese rodent models, AOD-9604 was reported to reduce weight gain and increase fat oxidation or lipolytic activity under specific experimental conditions. One study also reported that AOD-9604 did not compete for the classical growth-hormone receptor in the way intact hGH does.

These findings were one reason the molecule progressed into human development. However, animal metabolic effects cannot be assumed to predict meaningful weight loss in people.

What Happened in Human AOD-9604 Trials?

The human evidence is important because it places the preclinical results in context. AOD-9604 progressed through several human studies, including larger obesity trials.

According to FDA-reviewed material summarizing the development program, a large placebo-controlled study did not demonstrate the weight-loss effect required to support commercial development. The company reported that weight loss versus placebo at the planned endpoints was too small to reach statistical significance across the overall population.

This does not erase the earlier mechanistic or animal findings. It does mean that evidence of altered lipid metabolism in experimental systems should not be presented as proof of clinically meaningful human weight loss.

Does HGH Fragment 176-191 Have Human Clinical Evidence?

Robust controlled human efficacy data for HGH Fragment 176-191 itself are limited. Much of the later human development usually discussed alongside this topic relates to AOD-9604, a modified analogue.

For research interpretation, those evidence bases should remain separate. A study of AOD-9604 can help explain why the C-terminal region attracted interest, but it does not establish the efficacy of every related fragment.

Other Research on HGH Fragment 176-191

Research involving HGH Fragment 176-191 has not been limited entirely to metabolic questions. A 2022 laboratory study used the peptide as part of a nanoparticle system containing doxorubicin and examined effects in an MCF-7 breast-cancer cell model.

That work represents a very different experimental context and should not be interpreted as evidence of an established anticancer therapy. It does, however, illustrate that the fragment continues to be used as a research molecule outside the original metabolic literature.

HGH Fragment 176-191 Is Not Full-Length HGH

A short C-terminal fragment should not be treated as equivalent to intact 191-amino-acid human growth hormone. Full-length hGH has a broad endocrine signaling profile, including activity through the growth-hormone receptor and downstream pathways associated with IGF-1.

Fragment research was specifically motivated by the possibility that selected metabolic actions could be separated from some of those broader effects. Molecular size, receptor interactions and biological activity therefore differ between the fragment and the full hormone.

Analytical Identity Matters

Because several closely related sequences exist, analytical identity is particularly important for research involving HGH fragments. A product described as 176-191 should be distinguished from 177-191 and from modified analogues such as AOD-9604.

High-performance liquid chromatography can help characterize chromatographic purity, while mass spectrometry can support confirmation of molecular mass. For more background, see How Peptide Purity Is Tested and our guide to reading a peptide Certificate of Analysis.

Research Limitations

  • Many foundational studies are several decades old and were performed in animals or isolated tissues.
  • Different publications studied different C-terminal sequences, so results should not be automatically combined.
  • Antilipogenic activity is not the same endpoint as lipolysis or human weight loss.
  • Much of the later human evidence concerns AOD-9604 rather than unmodified HGH Fragment 176-191.
  • Large human AOD-9604 obesity trials did not establish a clinically meaningful overall weight-loss advantage over placebo.

Key Research Takeaway

HGH Fragment 176-191 belongs to a long-running line of research investigating whether metabolic actions of growth hormone can be localized to its C-terminal region. Early studies showed biological activity from several C-terminal fragments, while later research on related sequences explored adipose-tissue metabolism, fat oxidation and body-weight models.

The strongest interpretation is also the most precise: HGH Fragment 176-191, hGH 177-191 and AOD-9604 are related research compounds, but they are not interchangeable. Preclinical metabolic findings are scientifically relevant, while later human AOD-9604 trials show why those findings should not be translated directly into human efficacy claims.

Research Product Information

Peps In Bulk lists HGH Fragment 176-191 in 10-vial research packs with multiple strength options. Current pricing, available variations and pack information are shown on the product page.

References

For research and educational purposes only. This article is not medical advice.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *